Biovitrum Initiates Clinical Phase II Study of Glaucoma Treatment

17-Oct-2006

Biovitrum has initiated a clinical Phase II study with the candidate drug BVT.28949, a 5-HT2A antagonist for the treatment glaucoma. The results are expected to be available midyear of 2007.

The Phase II study includes 150 patients with an elevated intraocular pressure (a hallmark of glaucoma) and is placebo-controlled. It is carried out at several clinics in both Sweden and Ukraine.

The current hypothesis is that BVT.28949 reduces intraocular pressure by stimulating the outflow of aqueous humor through a mechanism different from that of presently available products, which means that BVT.28949 could function as a monotherapy or as a combination alternative with existing products.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances